title: Recurrence of sellar and suprasellar tumors in children treated with hGH--relation to immunohistochemical study on GH receptor.
abstract: OBJECTIVE
  GH replacement therapy is required in the majority of children with GH deficiency after treatment of sellar and suprasellar tumors. Owing to the high cell proliferative ability of human GH (hGH), its influence on tumor recurrence has been debated. We retrospectively studied the immunohistochemical expression of the GH receptor in various tumor tissues, in order to investigate the relation between tumor recurrence and hGH replacement.
  
  
  METHODS
  GH replacement therapy was performed in 25 patients (8 boys and 17 girls) after the treatment. Tumor recurrence was noted in 4 patients (craniopharyngioma: 2 patients, pilocytic astrocytoma and germinoma: 1 each). Immunohistochemical study of GH receptor in tumor tissue was carried out in those recurrent and recurrence-free cases, by using MAb 263 as a primary antibody.
  
  
  RESULTS
  Two patients with recurrent craniopharyngioma were positive for MAb 263, but 1 recurrence-free patient was negative. Patients with pilocytic astrocytoma (recurrent and recurrence-free: 1 each) were all positive. Five patients with germinoma (1 with recurrence and 4 without recurrence) were all negative.
  
  
  CONCLUSIONS
  In the patients with craniopharyngioma treated with GH, a positive immunohistochemical expression of GH receptor in tumor tissue may indicate a high probability of recurrence. In our cases, GH receptor was positive in astrocytomas and negative in germinomas, with or without recurrence. It is therefore speculated that each brain tumor may have its specificity in GH receptor expression.
authors.affiliation: Department of Neurological Surgery, Chiba University School of Medicine, Chiba-shi, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Uchino
authors.forename: N
authors.initials: N
authors.lastname: Saeki
authors.forename: Y
authors.initials: Y
authors.lastname: Iwadate
authors.forename: T
authors.initials: T
authors.lastname: Yasuda
authors.forename: S
authors.initials: S
authors.lastname: Konda
authors.forename: T
authors.initials: T
authors.lastname: Watanabe
authors.forename: K
authors.initials: K
authors.lastname: Wada
authors.forename: I
authors.initials: I
authors.lastname: Kazukawa
authors.forename: Y
authors.initials: Y
authors.lastname: Higuchi
authors.forename: T
authors.initials: T
authors.lastname: Iuchi
authors.forename: I
authors.initials: I
authors.lastname: Tatsuno
authors.forename: A
authors.initials: A
authors.lastname: Yamaura
mesh_terms: D000293:Adolescent; D001254:Astrocytoma / Q000188:drug therapy* / Q000378:metabolism; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D002648:Child; D003397:Craniopharyngioma / Q000188:drug therapy* / Q000378:metabolism; D005260:Female; D018237:Germinoma / Q000188:drug therapy* / Q000378:metabolism; D019382:Human Growth Hormone / Q000627:therapeutic use*; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000378:metabolism; D010911:Pituitary Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D011986:Receptors, Somatotropin / Q000378:metabolism; D012189:Retrospective Studies; D012658:Sella Turcica
chemical_list: D011986:Receptors, Somatotropin; D019382:Human Growth Hormone